Gene · 599
Papers4,142
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 4,142
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The transcriptomics profiling of blood CD4 and CD8 T-cells in narcolepsy type I. | Front Immunol | 2023 | 38077397 | PubTator, text mining | PubMed |
| The role of cellular senescence in skin aging and age-related skin pathologies. | Front Physiol | 2023 | 38074322 | PubTator, text mining | PubMed |
| Recent Updates in Venetoclax Combination Therapies in Pediatric Hematological Malignancies. | Int J Mol Sci | 2023 | 38069030 | PubTator, text mining | PubMed |
| New Insights into YAP/TAZ-TEAD-Mediated Gene Regulation and Biological Processes in Cancer. | Cancers (Basel) | 2023 | 38067201 | PubTator, text mining | PubMed |
| Clinical forecasting of acute myeloid leukemia using ex vivo drug-sensitivity profiling. | Cell Rep Methods | 2023 | 38065095 | PubTator, text mining | PubMed |
| Emerging role and therapeutic implications of p53 in intervertebral disc degeneration. | Cell Death Discov | 2023 | 38040675 | PubTator, text mining | PubMed |
| An untapped window of opportunity for glioma: targeting therapy-induced senescence prior to recurrence. | NPJ Precis Oncol | 2023 | 38030881 | PubTator, text mining | PubMed |
| Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature review. | Front Pharmacol | 2023 | 38026941 | PubTator, text mining | PubMed |
| Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study. | Cell Rep Med | 2023 | 38016482 | PubTator, text mining | PubMed |
| Inhibition of SF3B1 improves the immune microenvironment through pyroptosis and synergizes with αPDL1 in ovarian cancer. | Cell Death Dis | 2023 | 38012150 | PubTator, text mining | PubMed |
| MicroRNA-Mediated Regulation of Histone-Modifying Enzymes in Cancer: Mechanisms and Therapeutic Implications. | Biomolecules | 2023 | 38002272 | PubTator, text mining | PubMed |
| The mechanisms of tanshinone in the treatment of tumors. | Front Pharmacol | 2023 | 37964867 | PubTator, text mining | PubMed |
| Breast Cancer Chemoresistance: Insights into the Regulatory Role of lncRNA. | Int J Mol Sci | 2023 | 37958880 | PubTator, text mining | PubMed |
| Mesenchymal Stem Cell Microvesicles from Adipose Tissue: Unraveling Their Impact on Primary Ovarian Cancer Cells and Their Therapeutic Opportunities. | Int J Mol Sci | 2023 | 37958844 | PubTator, text mining | PubMed |
| Role of Non-Coding RNAs in Hepatocellular Carcinoma Progression: From Classic to Novel Clinicopathogenetic Implications. | Cancers (Basel) | 2023 | 37958352 | PubTator, text mining | PubMed |
| Using graph-based model to identify cell specific synthetic lethal effects. | Comput Struct Biotechnol J | 2023 | 37920819 | PubTator, text mining | PubMed |
| 7,8-Dihydroxy Flavone Induces Apoptosis via Upregulation of Caspase-3 in Human Hepatocarcinoma Cell. | Eurasian J Med | 2023 | 37909190 | PubTator, text mining | PubMed |
| Function and biomedical implications of exosomal microRNAs delivered by parenchymal and nonparenchymal cells in hepatocellular carcinoma. | World J Gastroenterol | 2023 | 37900996 | PubTator, text mining | PubMed |
| Bcl-B: an "unknown" protein of the Bcl-2 family. | Biol Direct | 2023 | 37899453 | PubTator, text mining | PubMed |
Synthesis and Biological Evaluation of Some New 3-Aryl-2-thioxo-2,3-dihydroquinazolin-4(1H)-ones and 3-Aryl-2-(benzylthio)quinazolin-4(3H)-ones as Antioxidants; COX-2, LDHA, α-Glucosidase and α-Amylase Inhibitors; and Anti-Colon Carcinoma and Apoptosis-Inducing Agents. | Pharmaceuticals (Basel) | 2023 | 37895863 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/599/papers?page=7